Notably, in this investigation, CD58 expression significantly surpassed levels in low-grade gliomas (WHO I-II) in high-grade gliomas (WHO III-IV), particularly in aggressive molecular subtypes like IDH wild-type and 1p19q non-codeletion. Here, CD58 is linked to central nervous system cancer.